<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269893</url>
  </required_header>
  <id_info>
    <org_study_id>CR006268</org_study_id>
    <secondary_id>C0116T09</secondary_id>
    <nct_id>NCT00269893</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty</brief_title>
  <official_title>A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of abciximab (an
      anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter study evaluating the
      efficacy and safety of abciximab, an anti-platelet therapy, in patients undergoing high risk
      coronary angioplasty. The primary outcomes of the study include any of the following: the
      number of deaths from any cause, or myocardial infarctions and recurrent ischemic events
      requiring urgent intervention (e.g., repeat angioplasty, coronary artery bypass surgery,
      intracoronary stent placement, or intra-aortic balloon pump).

      Patients receive an abciximab bolus, abciximab bolus plus infusion, or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1991</start_date>
  <completion_date type="Actual">November 1992</completion_date>
  <primary_completion_date type="Actual">November 1992</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any of the following within 30 days: Death from any cause; Myocardial infarction; Recurrent ischemic event requiring urgent intervention (repeat angioplasty, coronary artery bypass surgery, intracoronary stent placement, or intra-aortic balloon pump).</measure>
    <time_frame>30 days after angioplasty</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants With use of thrombolytic agent in catheterization lab</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in catheterization lab</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of balloon Used inflations during angioplasty</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Successful Angioplasty</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for Specific Mortality</measure>
    <time_frame>Up to end of study (30 days after angioplasty)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with late major clinical events</measure>
    <time_frame>30 days after angioplasty up to 6 months after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Abrupt Closure</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2038</enrollment>
  <condition>Angina, Unstable</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>0.25 mg/kg of body weight of abciximab either bolus or infusion.</description>
    <arm_group_label>Abciximab and Placebo</arm_group_label>
    <arm_group_label>Abciximab</arm_group_label>
    <other_name>c7E3 Fab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo soulution either bolus or infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Abciximab and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for elective or urgent coronary balloon angioplasty or atherectomy
             with an FDA-approved device in one of the following settings: unstable angina or non-Q
             wave myocardial infarction, acute Q-wave myocardial infarction, or high-risk
             clinical/morphological characteristics

        Exclusion Criteria:

          -  Patients with a history of hemorrhagic diathesis - Having had major surgery or
             clinically significant gastrointestinal or genitourinary bleeding within 6 weeks of
             study enrollment

          -  Having had a stroke within 2 years prior to enrollment or any stroke with significant
             residual neurological deficit

          -  Having occlusion of the left main coronary artery greater than 50% or a history of
             vasculitis

          -  Treated with oral anticoagulants within 7 days (unless prothrombin time is =&lt; 1.2
             times control) or intravenous dextran (before or planned for during the treatment
             angioplasty)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <results_reference>
    <citation>EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994 Apr 7;330(14):956-61.</citation>
    <PMID>8121459</PMID>
  </results_reference>
  <results_reference>
    <citation>Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997 Aug 13;278(6):479-84.</citation>
    <PMID>9256222</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2005</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abciximab</keyword>
  <keyword>Angina, unstable</keyword>
  <keyword>Angioplasty, transluminal, Percutaneous coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

